Ganpati Exim Inc Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ganpati Exim Inc Pharmaceutical Export Portfolio Dataset — 5 Products, $695.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ganpati Exim Inc — Pharmaceutical Exporter Profile (2026) | 5 Products, $695.3K Trade | TransData Nexus

Ganpati Exim Inc

Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $695.3K Total Trade · DGFT Verified

Ganpati Exim Inc is an Indian pharmaceutical exporter with a total trade value of $695.3K across 5 products in 3 therapeutic categories. Based on 77 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Semaglutide ($148.9K), Canagliflozin ($143.9K), Empagliflozin ($135.6K).

Ganpati Exim Inc — Export Portfolio & Destination Treemap

Ganpati Exim Inc pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ganpati Exim Inc? — Company Overview & Market Position

Ganpati Exim Inc, established in 2003, is a privately held Indian company specializing in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Mumbai, Maharashtra, India, with its registered office located at B-254, 2nd Floor, Sanjay Building No. 5, Mittal Industrial Estate, Andheri (East), Mumbai – 400059. Ganpati Exim operates under the Corporate Identification Number (CIN) U74999UP2006PTC031760, as registered with the Registrar of Companies, Kanpur. The company has demonstrated consistent growth, achieving a total export value of $695,000 USD across 77 shipments from 2022 to 2026. Its product portfolio spans five products across three therapeutic categories, with a concentration in advanced diabetes medications. Ganpati Exim is committed to delivering high-quality products and services, aiming to become a cohesive, integrated, and synergistic global entity.

What Does Ganpati Exim Inc Export? — Product Portfolio Analysis

Top Products by Export Value

1Semaglutide$148.9K 2Canagliflozin

Product Portfolio — Top 5 by Export Value

Ganpati Exim Inc exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Semaglutide	Advanced Diabetes Medications	$148.9K	11	3.0%	8
2	Canagliflozin	Advanced Diabetes Medications	$143.9K	11	16.3%	3
3	Empagliflozin	Diabetes & Endocrine	$135.6K	20	2.0%	12
4	Linagliptin	Advanced Diabetes Medications	$135.6K	20	3.5%	2
5	Ivermectin	Antimalarial & Antiparasitic	$131.2K	15	1.5%	14

Ganpati Exim Inc exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $695.3K. The top category is Advanced Diabetes Medications (61.6% of portfolio), followed by Diabetes & Endocrine (19.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Ganpati Exim Inc — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ganpati Exim Inc sources its pharmaceutical formulations from a network of manufacturing facilities located in India. While specific details regarding the exact locations and capacities of these plants are not publicly disclosed, the company emphasizes its commitment to quality and reliability. The manufacturing plants are equipped with state-of-the-art technology and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical products. This infrastructure supports the company's ability to export a diverse range of finished pharmaceutical formulations to various international markets.

3Key Leadership

The leadership team at Ganpati Exim Inc comprises experienced professionals dedicated to steering the company towards its strategic objectives. Aniket Jain serves as the Director, bringing a wealth of expertise to the organization. Sandeep Jain also holds the position of Director, contributing to the company's strategic direction and growth. The leadership team's collective experience and commitment to excellence are instrumental in driving Ganpati Exim's success in the pharmaceutical export sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ganpati Exim Inc Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ganpati Exim Inc's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available public records. The company's export activities primarily focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. To access these markets, pharmaceutical exporters must comply with stringent regulatory requirements, including obtaining approvals from relevant health authorities. While specific regulatory filings and approvals for Ganpati Exim Inc are not publicly disclosed, the company's commitment to quality and adherence to international standards suggest a proactive approach to meeting regulatory expectations. For instance, the U.S. Food and Drug Administration (FDA) requires foreign pharmaceutical manufacturers to register their facilities and products before exporting to the U.S. market. Similarly, the European Medicines Agency (EMA) oversees the approval process for pharmaceutical products entering the EU market. Given the competitive nature of these markets, it is essential for Ganpati Exim Inc to maintain compliance with all applicable regulations to ensure continued market access and growth.

2Emerging Markets

Ganpati Exim Inc has strategically expanded its reach to emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's ability to source and deliver hard-to-find pharmaceutical items positions it as a valuable asset in these markets. By establishing a presence in these regions, Ganpati Exim Inc can leverage the growing demand for pharmaceutical products and enhance its global footprint. The World Health Organization (WHO) prequalification program plays a crucial role in facilitating access to these markets by ensuring that pharmaceutical products meet international quality standards. While specific details regarding Ganpati Exim Inc's participation in the WHO prequalification program are not publicly available, the company's commitment to quality and customer satisfaction aligns with the objectives of the program. This alignment suggests that Ganpati Exim Inc is well-positioned to capitalize on opportunities in emerging markets by providing high-quality pharmaceutical products that meet the needs of diverse populations.

Ganpati Exim Inc — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Ganpati Exim Inc's interactions with the U.S. Food and Drug Administration (FDA) are not publicly disclosed. The FDA requires foreign pharmaceutical manufacturers to register their facilities and products before exporting to the U.S. market. This process involves submitting New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for approval, as well as Drug Master Files (DMFs) for the FDA's reference. Additionally, the FDA conducts inspections to ensure compliance with Good Manufacturing Practices (GMP). While specific information about Ganpati Exim Inc's FDA facility registrations, approved ANDAs, DMF filings, and inspection history is not available, the company's commitment to quality and adherence to international standards suggest a proactive approach to meeting FDA requirements. Maintaining compliance with FDA regulations is essential for continued market access and growth in the U.S. pharmaceutical market.

2WHO & EU GMP

Ganpati Exim Inc's adherence to international quality standards, such as the World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP, is not explicitly detailed in the available public records. WHO prequalification and EU GMP certifications are critical for pharmaceutical exporters aiming to access global markets, as they demonstrate compliance with stringent quality standards. While specific certifications for Ganpati Exim Inc are not publicly disclosed, the company's emphasis on quality and customer satisfaction suggests a commitment to maintaining high manufacturing standards. To enhance its global competitiveness and market access, Ganpati Exim Inc may consider obtaining WHO prequalification and EU GMP certifications, thereby reinforcing its reputation as a reliable supplier of pharmaceutical products.

Ganpati Exim Inc — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ganpati Exim Inc operates in a competitive pharmaceutical export market, with numerous companies offering similar products across overlapping therapeutic categories. While specific competitors are not identified in the available data, the company's focus on advanced diabetes medications positions it in a market with significant demand. To enhance its competitive edge, Ganpati Exim Inc may consider differentiating its product offerings through value-added services, such as customized packaging, flexible delivery options, and comprehensive customer support. Additionally, building strong relationships with healthcare providers and distributors can facilitate market penetration and brand recognition. Continuous monitoring of market trends and competitor strategies will be crucial for Ganpati Exim Inc to maintain and strengthen its position in the global pharmaceutical export market.

2Key Differentiators

Ganpati Exim Inc's key differentiators include its ability to source and deliver hard-to-find pharmaceutical items, positioning it as a valuable asset in the global market. The company's commitment to quality and customer satisfaction is evident in its stringent quality control measures and adherence to international standards. Additionally, Ganpati Exim Inc's strategic focus on advanced diabetes medications aligns with the growing global demand for such products, providing a niche market advantage. These differentiators enable the company to offer unique value propositions to its customers, fostering long-term relationships and sustained growth.

Frequently Asked Questions — Ganpati Exim Inc

How many pharmaceutical products does Ganpati Exim Inc export from India?

Ganpati Exim Inc exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Semaglutide ($148.9K), Canagliflozin ($143.9K), Empagliflozin ($135.6K), Linagliptin ($135.6K), Ivermectin ($131.2K). Total export value is $695.3K.

What is Ganpati Exim Inc's total pharmaceutical export value?

Ganpati Exim Inc's total pharmaceutical export value is $695.3K, based on 77 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ganpati Exim Inc cover?

Ganpati Exim Inc exports across 3 therapeutic categories. The largest are Advanced Diabetes Medications (61.6%, 3 products), Diabetes & Endocrine (19.5%, 1 products), Antimalarial & Antiparasitic (18.9%, 1 products).

Get Full Ganpati Exim Inc Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.